Innoviva Gross Margin 2010-2024 | INVA

Current and historical gross margin for Innoviva (INVA) over the last 10 years. The current gross profit margin for Innoviva as of March 31, 2024 is %.
Innoviva Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $0.31B $0.27B 86.50%
2023-12-31 $0.31B $0.27B 86.45%
2023-09-30 $0.29B $0.25B 86.55%
2023-06-30 $0.29B $0.26B 88.97%
2023-03-31 $0.32B $0.29B 92.74%
2022-12-31 $0.33B $0.32B 96.07%
2022-09-30 $0.37B $0.37B 99.20%
2022-06-30 $0.40B $0.40B 100.00%
2022-03-31 $0.40B $0.40B 100.00%
2021-12-31 $0.39B $0.39B 100.00%
2021-09-30 $0.38B $0.38B 100.00%
2021-06-30 $0.37B $0.37B 100.00%
2021-03-31 $0.34B $0.34B 100.00%
2020-12-31 $0.34B $0.34B 100.00%
2020-09-30 $0.32B $0.32B 100.00%
2020-06-30 $0.30B $0.30B 100.00%
2020-03-31 $0.29B $0.29B 100.00%
2019-12-31 $0.26B $0.26B 100.00%
2019-09-30 $0.27B $0.27B 100.00%
2019-06-30 $0.26B $0.26B 100.00%
2019-03-31 $0.26B $0.26B 100.00%
2018-12-31 $0.26B $0.26B 100.00%
2018-09-30 $0.25B $0.25B 100.00%
2018-06-30 $0.24B $0.24B 100.00%
2018-03-31 $0.23B $0.23B 100.00%
2017-12-31 $0.22B $0.22B 100.00%
2017-09-30 $0.19B $0.19B 100.00%
2017-06-30 $0.18B $0.18B 100.00%
2017-03-31 $0.15B $0.15B 100.00%
2016-12-31 $0.13B $0.13B 100.00%
2016-09-30 $0.11B $0.11B 100.00%
2016-06-30 $0.09B $0.09B 100.00%
2016-03-31 $0.07B $0.07B 100.00%
2015-12-31 $0.06B $0.06B 100.00%
2015-09-30 $0.04B $0.04B 100.00%
2015-06-30 $0.03B $0.03B 100.00%
2015-03-31 $0.02B $0.02B 100.00%
2014-12-31 $0.01B $0.01B 100.00%
2014-09-30 $0.00B $0.00B 100.00%
2014-06-30 $0.00B $0.00B 100.00%
2014-03-31 $0.00B $0.00B 100.00%
2013-12-31 $0.00B $0.00B 100.00%
2013-09-30 $0.01B $0.01B 100.00%
2013-06-30 $0.01B $0.01B 100.00%
2013-03-31 $0.01B $0.01B 100.00%
2012-12-31 $0.14B $0.14B 100.00%
2012-09-30 $0.13B $0.13B 100.00%
2012-06-30 $0.14B $0.14B 100.00%
2012-03-31 $0.14B $0.14B 100.00%
2011-12-31 $0.02B $0.02B 100.00%
2011-09-30 $0.03B $0.03B 100.00%
2011-06-30 $0.02B $0.02B 100.00%
2011-03-31 $0.02B $0.02B 100.00%
2010-12-31 $0.02B $0.02B 100.00%
2010-09-30 $0.02B $0.02B 100.00%
2010-06-30 $0.02B $0.02B 100.00%
2010-03-31 $0.02B $0.02B 100.00%
2009-12-31 $0.03B $0.03B 100.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.013B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27